Allergan (AGN) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Piper Jaffray Remains Sidelined on Allergan (AGN) Following Mixed 2Q
August 9, 2016 9:08 AM EDTPiper Jaffray maintained a Neutral rating on Allergen (NYSE: AGN), and cut the price target to $227.00 (from $236.00), following the company's 2Q earnings report. AGN reported non-GAAP diluted EPS of $3.35 on revenue of $3.68B, compared to Street estimates of $3.33 and $3.97B, respectively.
Analyst David Amsellem commented, "Allergan... More
Allergan (AGN) CEO Says Not Focused on or Looking at Large Deals (BIIB)
August 8, 2016 9:21 AM EDTAllergan's (NYSE: AGN) CEO said the company isn't focused on or looking at large deals.
Traders are watching shares of rumored target Biogen (NASDAQ: BIIB) following the comments.
... MoreAllergan (AGN) August weekly volatility flat into Q2 and outlook
August 8, 2016 6:18 AM EDTAllergan (NYSE: AGN) August weekly call option implied volatility is at 35, August and September is at 28; compared to its 52-week range of 20 to 53 into the expected release of Q2 results today.
... More